To evaluate racial, gender, and socioeconomic differences in the treatment of metastatic renal cell carcinoma (mRCC) and their impact on survival.
Patients aged ≥18 years diagnosed with mRCC in the National Cancer Database (2004-2015) were analyzed.
To evaluate racial, gender, and socioeconomic differences in the treatment of metastatic renal cell carcinoma (mRCC) and their impact on survival.
Patients aged ≥18 years diagnosed with mRCC in the National Cancer Database (2004-2015) were analyzed.